Abstract
Duchenne muscular dystrophy (DMD), an X-linked inherited musclewasting disease primarily affecting young boys with prevalence of between1:3,500- 1:5,000, is a rare genetic disease caused by defects in the gene for dystrophin. Dystrophin protein is critical to the stability of myofibers in skeletal and cardiac muscle. There is currently no cure available to ameliorate DMD and/or its patho-physiology. A number of therapeutic strategies including molecular-based therapeutics that replace or correct the missing or nonfunctional dystrophin protein have been devised to correct the patho-physiological consequences induced by dystrophin absence. We will review the current in vivo experimentation status (including preclinical models and clinical trials) for two of these approaches, namely: 1) Adeno-associated virus (AAV) mediated (micro) dystrophin gene augmentation/ supplementation and 2) Antisense oligonucleotide (AON)-mediated exon skipping strategies.
Keywords: Adeno-associated virus (AAV), Antisense oligonucleotides (AONs), Duchenne muscular dystrophy (DMD), Dystrophin, Exon skipping, In vivo.
Current Gene Therapy
Title:Adeno-Associated Virus (AAV) Mediated Dystrophin Gene Transfer Studies and Exon Skipping Strategies for Duchenne Muscular Dystrophy (DMD)
Volume: 15 Issue: 4
Author(s): Klaudia Kawecka, Michael Theodoulides, Yalin Hasoglu, Susan Jarmin, Hanna Kymalainen, Anita Le-Heron, Linda Popplewell, Alberto Malerba, George Dickson and Takis Athanasopoulos
Affiliation:
Keywords: Adeno-associated virus (AAV), Antisense oligonucleotides (AONs), Duchenne muscular dystrophy (DMD), Dystrophin, Exon skipping, In vivo.
Abstract: Duchenne muscular dystrophy (DMD), an X-linked inherited musclewasting disease primarily affecting young boys with prevalence of between1:3,500- 1:5,000, is a rare genetic disease caused by defects in the gene for dystrophin. Dystrophin protein is critical to the stability of myofibers in skeletal and cardiac muscle. There is currently no cure available to ameliorate DMD and/or its patho-physiology. A number of therapeutic strategies including molecular-based therapeutics that replace or correct the missing or nonfunctional dystrophin protein have been devised to correct the patho-physiological consequences induced by dystrophin absence. We will review the current in vivo experimentation status (including preclinical models and clinical trials) for two of these approaches, namely: 1) Adeno-associated virus (AAV) mediated (micro) dystrophin gene augmentation/ supplementation and 2) Antisense oligonucleotide (AON)-mediated exon skipping strategies.
Export Options
About this article
Cite this article as:
Kawecka Klaudia, Theodoulides Michael, Hasoglu Yalin, Jarmin Susan, Kymalainen Hanna, Le-Heron Anita, Popplewell Linda, Malerba Alberto, Dickson George and Athanasopoulos Takis, Adeno-Associated Virus (AAV) Mediated Dystrophin Gene Transfer Studies and Exon Skipping Strategies for Duchenne Muscular Dystrophy (DMD), Current Gene Therapy 2015; 15 (4) . https://dx.doi.org/10.2174/1566523215666150710123830
DOI https://dx.doi.org/10.2174/1566523215666150710123830 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sympathetic Nervous System in Patients with Sleep Related Breathing Disorders
Current Hypertension Reviews Beta-Blockers (Carvedilol) in Children with Systemic Ventricle Systolic Dysfunction - Systematic Review and Meta-Analysis
Reviews on Recent Clinical Trials Inhibitory Effect of Fruit Juices on the Doxorubicin Metabolizing Activity of Carbonyl Reductase 1
Drug Metabolism Letters Nitric Oxide in Cardiac Transplantation
Vascular Disease Prevention (Discontinued) Cardiac Stem Cell-Based Myocardial Regeneration: Towards a Translational Approach
Cardiovascular & Hematological Agents in Medicinal Chemistry Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology Secondary Prevention of Ischemic Stroke
Current Drug Targets Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases
Cardiovascular & Hematological Disorders-Drug Targets Low Molecular Weight Heparins and Glomerular Filtration Rate: A Report to be Considered
Current Vascular Pharmacology Heart Failure in East Asia
Current Cardiology Reviews Meet Our Regional Editor
Current Vascular Pharmacology Are the Antioxidant Properties of Carvedilol Important for the Protection of Cardiac Mitochondria?
Current Vascular Pharmacology Common Variants for Heart Failure
Current Genomics Pharmacogenomics of the Human ATP-Binding Cassette Transporter ABCG2
Current Pharmacogenomics Dapagliflozin Protects H9c2 Cells Against Injury Induced by Lipopolysaccharide via Suppression of CX3CL1/CX3CR1 Axis and NF-κB Activity
Current Molecular Pharmacology Anticancer Drug Combinations, How Far We can Go Through?
Anti-Cancer Agents in Medicinal Chemistry Incretin-Based Therapy of Type 2 Diabetes Mellitus
Current Protein & Peptide Science PI3K Pathway Inhibitors: Better Not Left Alone
Current Pharmaceutical Design The Role of Heat Shock Protein (HSP) in Atherosclerosis: Pathophysiology and Clinical Opportunities
Current Medicinal Chemistry Unfolded Protein Response as a Therapeutic Target in Cardiovascular Disease
Current Topics in Medicinal Chemistry